ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Should Adults Aged 26 to 45 Years Receive the Human Papillomavirus Vaccine?

by Brooke M. Su-Velez, MD, MPH, and Maie A. St. John, MD, PhD • January 15, 2021

  • Tweet
  • Email
Print-Friendly Version

TRIO Best PracticeTRIO Best Practice articles are brief, structured reviews designed to provide the busy clinician with a handy outline and reference for day-to-day clinical decision making. The ENTtoday summaries below include the Background and Best Practice sections of the original article. To view the complete Laryngoscope article free of charge, visit Laryngoscope.

You Might Also Like

No related posts.

Explore This Issue
January 2021

 

Background

The human papillomavirus (HPV) vaccine has been available in the United States since 2006 and was first approved by the FDA for both men and women aged 9 to 26 years; this was increased to ages 9 to 45 years in 2018. In August 2019, the Advisory Committee on Immunization Practices (ACIP) stated that, although it did not recommend routine vaccination for adults aged 27 to 45 years, some patients in this age group may be at risk for new HPV infection, and thus a process of shared clinical decision-making could be used regarding vaccination in this cohort (MMWR Morb Mortal Wkly Rep. 2019;68:698-702). The current vaccine protects against nine different HPV types causing HPV-associated cancers (about 34,000 cases annually in the U.S.) and anogenital warts. The vaccine has been demonstrated to be both safe and effective. Despite only about 60% vaccine uptake among adolescents, the prevalence of HPV infections has declined among young women and also in some unvaccinated groups (ibid).

Despite FDA approval, the ACIP did not recommend routine vaccination for adults due to the rationale that the vaccine is most effective before any exposure to HPV has occurred, and several cost-effectiveness analyses have demonstrated little additional benefit in vaccinating adults on a population level. However, new oropharyngeal cancer cases per year now outnumber cases of cervical cancer in the U.S. and affect more men than women (ibid; J Clin Oncol. 2018;36:262-267). Since ACIP recommendations become official U.S. vaccine policy, there is a risk that a lack of recommendation may be perceived as a recommendation against vaccination. As otolaryngologists and head and neck surgeons, we have an important role to play in counseling patients regarding the HPV vaccine. Despite the ACIP statement, should we be recommending HPV vaccination for our adult patients aged 26 to 45 years?

Best Practice

Based on studies of the previously available bivalent and quadrivalent HPV vaccines, the current HPV vaccine is safe and proves efficacious in both adult women and men aged over 26 years, even in individuals with prior HPV exposure. (Lancet Infect Dis. 2016;16:1154-1168; Gynecol Oncol. 2013;130:264–268; Vaccine. 2019;37:2864–2869). In the gynecologic literature, the HPV vaccine also demonstrates the potential to reduce the recurrence of precancerous lesions caused by HPV infection (Gynecol Oncol. 2013;130:264–268). At current levels of HPV vaccine uptake in the eligible young adult population, especially the low rate in men, the impact of the vaccine on oral HPV prevalence is limited with regard to rising incidence of HPV-associated oropharyngeal cancers (J Clin Oncol. 2018;36:262-267). Although we as otolaryngologists do not often administer the HPV vaccine in our practices, the potential benefits of increasing vaccine uptake far outweigh the limited risks, and in the United States we do not face issues with adequate vaccine supply. We should be recommending the HPV vaccine to all our adult patients aged 26 to 45 years who have not yet been vaccinated.

Pages: 1 2 | Single Page

Filed Under: Otology/Neurotology, Otology/Neurotology, TRIO Best Practices Tagged With: clinical research, HPV vaccineIssue: January 2021

You Might Also Like:

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Complications for When Physicians Change a Maiden Name
    • Vertigo in the Elderly: What Does It Mean?
    • Neurogenic Cough Is Often a Diagnosis of Exclusion
    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • How To: A Modified Endoscopic Draf III Approach for Dermoid Cysts
    • How To: Inferior Meatus Augmentation Procedure for Empty Nose Syndrome
    • Otolaryngology Resident Says Art Helps Her Process Ideas on Wellness, Burnout
    • Age-Related Hearing Loss Is Associated with Incident Dementia in Adults Over 60
    • COVID-19 Associated with Upsurge in Otolaryngology Publications

Polls

Do you report near-miss or no-harm events to your patients?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2022 The Triological Society. All Rights Reserved.
ISSN 1559-4939